Szczylik, Cezary

Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma

Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 3,403

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Agarwal, N., Azad, A. A., Carles, J., Fay, A. P., Matsubara, N., Heinrich, D., Szczylik, C., De Giorgi, U., Young Joung, J., Fong, P. C. C., et al. (2023) · The Lancet

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 538

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: A randomized, double‐blind, placebo‐controlled, phase 2 study

Rini, B., Szczylik, C., Tannir, N. M., Koralewski, P., Tomczak, P., Deptala, A., Dirix, L. Y., Fishman, M., Ramlau, R., Ravaud, A., et al. (2012) · Cancer

Renal cell carcinoma treatmentAngiogenesis and VEGF in Cancer

Cited by 110

Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer

Cunningham, D., Sirohi, B., Pluzanska, A., Utracka-Hutka, B., Zaluski, J., Glynne-Jones, R., Koralewski, P., Bridgewater, J., Mainwaring, P., Wasan, H., et al. (2009) · Annals of Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 62

Growth factor-dependent inhibition of normal hematopoiesis by N-ras antisense oligodeoxynucleotides.

Skorski, T., Szczylik, C., Ratajczak, M. Z., Malaguarnera, L., Gewirtz, A. M., & Calabretta, B. (1992) · The Journal of experimental medicine

Hematopoietic Stem Cell TransplantationAcute Myeloid Leukemia Research

Cited by 52